Page 66 - 《中国药房》2023年19期

[15] LOMBARDI G，DE SALVO G L，BRANDES A A，et al. Anti-angiogenic therapy for high-grade glioma[J]. Co‐
Regorafenib compared with lomustine in patients with re‐ chrane Database Syst Rev，2018，11（11）：CD008218.
lapsed glioblastoma （REGOMA）：a multicentre，open- [28] WELLER M，VAN DEN BENT M，PREUSSER M，et al.
label，randomised，controlled，phase 2 trial[J]. Lancet On‐ EANO guidelines on the diagnosis and treatment of dif‐
col，2019，20（1）：110-119. fuse gliomas of adulthood[J]. Nat Rev Clin Oncol，2021，
[16] LE RHUN E，PREUSSER M，ROTH P，et al. Molecular 18（3）：170-186.
targeted therapy of glioblastoma[J]. Cancer Treat Rev， [29] 国家卫生健康委员会医政医管局，中国抗癌协会脑胶质
2019，80：101896. 瘤专业委员会，中国医师协会脑胶质瘤专业委员会. 脑
[17] TUNCEL G，KALKAN R. Receptor tyrosine kinase-ras- 胶质瘤诊疗指南：2022 版[J]. 中华神经外科杂志，2022，
PI3 kinase-Akt signaling network in glioblastoma multi‐ 38（8）：757-777.
forme[J]. Med Oncol，2018，35（9）：122. Medical Administration Bureau of National Health Com‐
[18] AGARWAL S，SURI V，SHARMA M C，et al. Therapy mission of the People’s Republic of China，Brain Glioma
and progression-induced O6-methylguanine-DNA methyl‐ Professional Committee of China Anti-Cancer Associa‐
transferase and mismatch repair alterations in recurrent tion，China Medical Doctor Association Brain Glioma Pro‐
glioblastoma multiforme[J]. Indian J Cancer，2015，52 fessional Committee of Chinese Medical Doctor Associa‐
（4）：568-573. tion. Diagnosis and treatment guidelines for brain glioma：
[19] LAWRIE T A，GILLESPIE D，DOWSWELL T，et al. 2022 edition[J]. Chin J Neurosur，2022，38（8）：757-777.
Long-term neurocognitive and other side effects of radio‐ [30] PUDUVALLI V K，WU J，YUAN Y，et al. A Bayesian
therapy，with or without chemotherapy，for glioma[J]. Co‐ adaptive randomized phase Ⅱ multicenter trial of bevaci‐
chrane Database Syst Rev，2019，8（8）：CD013047. zumab with or without vorinostat in adults with recurrent
[20] OLDRINI B，VAQUERO-SIGUERO N，MU Q H，et al. glioblastoma[J]. Neuro Oncol，2020，22（10）：1505-1515.
MGMT genomic rearrangements contribute to chemo‐ [31] SCHIFF D，JAECKLE K A，ANDERSON S K，et al.
therapy resistance in gliomas[J]. Nat Commun，2020，11 Phase 1/2 trial of temsirolimus and sorafenib in the treat‐
（1）：3883. ment of patients with recurrent glioblastoma：North Cen‐
[21] CHANG S S，ZHANG P X，CAIRNCROSS J G，et al. tral Cancer Treatment Group Study/Alliance N0572[J]. Can‐
Phase Ⅲ randomized study of radiation and temozolo‐ cer，2018，124（7）：1455-1463.
mide versus radiation and nitrosourea therapy for anapla- [32] VAN DEN BENT M，EOLI M，SEPULVEDA J M，et al.
stic astrocytoma：results of NRG Oncology RTOG 9813 INTELLANCE 2/EORTC 1410 randomized phase Ⅱ
[J]. Neuro Oncol，2017，19（2）：252-258. study of Depatux-M alone and with temozolomide vs te‐
[22] TAAL W，OOSTERKAMP H M，WALENKAMP A M，et mozolomide or lomustine in recurrent EGFR amplified
al. Single-agent bevacizumab or lomustine versus a combi‐ glioblastoma[J]. Neuro Oncol，2020，22（5）：684-693.
nation of bevacizumab plus lomustine in patients with re‐ [33] WEN P Y，TOUAT M，ALEXANDER B M，et al. Bupar-
current glioblastoma （BELOB trial）：a randomised con‐ lisib in patients with recurrent glioblastoma harboring
trolled phase 2 trial[J]. Lancet Oncol，2014，15（9）： phosphatidylinositol 3-kinase pathway activation：an open-
943-953. label，multicenter，multi-arm，phase Ⅱ trial[J]. J Clin On‐
[23] WICK W，GORLIA T，BENDSZUS M，et al. Lomustine col，2019，37（9）：741-750.
and bevacizumab in progressive glioblastoma[J]. N Engl J [34] DUERINCK J，FOUR S D，BOUTTENS F，et al. Rando-
Med，2017，377（20）：1954-1963. mized phase Ⅱ trial comparing axitinib with the combina‐
[24] KLEIJN A，VAN DEN BOSSCHE W，HAEFNER E，et al. tion of axitinib and lomustine in patients with recurrent
It-16 combination treatment with delta24-RGD and temo‐ glioblastoma[J]. J Neurooncol，2018，136（1）：115-125.
zolomide improves survival and affects intratumoral im‐ [35] NORDEN A D，SCHIFF D，AHLUWALIA M S，et al.
mune cell subsets in a murine malignant glioma model[J]. Phase Ⅱ trial of triple tyrosine kinase receptor inhibitor
Neuro Oncol，2014，16（suppl_5）：v112-v113. nintedanib in recurrent high-grade gliomas[J]. J Neuroon‐
[25] BRYANT J，BROWN M，GROMEIER M. Chemotherapy col，2015，121（2）：297-302.
enhances oncolytic recombinant poliovirus efficacy[J]. J [36] FROSINA G. Radiotherapy of high-grade gliomas：first
Immunother Cancer，2017，5（Suppl2）. half of 2021 update with special reference to radiosensiti‐
[26] KHASRAW M，AMERATUNGA M，LASSMAN A B， et zation studies[J]. Int J Mol Sci，2021，22（16）：8942.
al. A meta-analysis of antiangiogenic therapy for gliobla- （收稿日期：2023-03-15 修回日期：2023-08-07）
stoma（GBM）[J]. J Clin Oncol，2014，32（15_suppl）：2047. （编辑：刘明伟）
[27] AMERATUNGA M，PAVLAKIS N，WHEELER H，et al.

· 2364 · China Pharmacy 2023 Vol. 34 No. 19 中国药房 2023年第34卷第19期